NCT03993821 - Burosumab for CSHS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

October 30, 2022

Study Completion Date

March 31, 2023

Conditions

Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)Epidermal Nevus Syndrome

Interventions

DRUG

Burosumab

Burosumab, the investigational product, is a recombinant human IgG1 monoclonal antibody targeting FGF23. It is supplied as a sterile, clear, colorless and preservative-free solution and is administered via subcutaneous injection.

Trial Locations (1)

20010

Children's National Hospital, Washington D.C.